309
Views
12
CrossRef citations to date
0
Altmetric
Research Article

The autoantigen Pso p27: A post-translational modification of SCCA molecules

, &
Pages 229-234 | Received 01 Sep 2010, Accepted 06 Oct 2010, Published online: 14 Jan 2011
 

Abstract

Pso p27 is a protein antigen expressed in psoriatic lesions and is shown to participate in complement activating immune complexes in the affected skin.

The objective of the present study was sequencing of the Pso p27 protein in an approach to identify a “Pso p27 gene”. The analyses showed that Pso p27 represents several proteins with homologies to various Squamous Cell Carcinoma Antigens (SCCAs). The unique N-terminal and C-terminal ends of Pso p27, however, differ from the terminal ends of the SCCA molecules and indicate posttranslational digestions of SCCA molecules with highly specific endoproteases.

These structural variations may play crucial roles with respect to the immunogenicity of Pso p27 and the failure of immunological tolerance.

Acknowledgements

Thanks to the FUGE Proteomics Laboratory, Norwegian University of Science and Technology for assistance with methods and instruments.

Declaration of interest: The work has been supported by grants from The Research Council of Norway. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.